AU2006256891B2 - Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection - Google Patents

Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection Download PDF

Info

Publication number
AU2006256891B2
AU2006256891B2 AU2006256891A AU2006256891A AU2006256891B2 AU 2006256891 B2 AU2006256891 B2 AU 2006256891B2 AU 2006256891 A AU2006256891 A AU 2006256891A AU 2006256891 A AU2006256891 A AU 2006256891A AU 2006256891 B2 AU2006256891 B2 AU 2006256891B2
Authority
AU
Australia
Prior art keywords
autoimmune
disease
ides
syndrome
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2006256891A
Other languages
English (en)
Other versions
AU2006256891A1 (en
Inventor
Lars Bjorck
Rikard Holmdahl
Kutty Selva Nandakumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511769A external-priority patent/GB0511769D0/en
Priority claimed from GB0605781A external-priority patent/GB0605781D0/en
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of AU2006256891A1 publication Critical patent/AU2006256891A1/en
Application granted granted Critical
Publication of AU2006256891B2 publication Critical patent/AU2006256891B2/en
Assigned to Hansa Biopharma AB reassignment Hansa Biopharma AB Request to Amend Deed and Register Assignors: HANSA MEDICAL AB
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2006256891A 2005-06-09 2006-06-08 Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection Expired AU2006256891B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0511769A GB0511769D0 (en) 2005-06-09 2005-06-09 Treatment
GB0511769.2 2005-06-09
GB0605781A GB0605781D0 (en) 2006-03-22 2006-03-22 Treatment
GB0605781.4 2006-03-22
PCT/EP2006/005454 WO2006131347A2 (en) 2005-06-09 2006-06-08 Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Publications (2)

Publication Number Publication Date
AU2006256891A1 AU2006256891A1 (en) 2006-12-14
AU2006256891B2 true AU2006256891B2 (en) 2011-08-04

Family

ID=36952007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006256891A Expired AU2006256891B2 (en) 2005-06-09 2006-06-08 Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Country Status (14)

Country Link
US (1) US8133483B2 (enExample)
EP (1) EP1901773B1 (enExample)
JP (1) JP5427409B2 (enExample)
CN (1) CN105770871A (enExample)
AT (1) ATE548049T1 (enExample)
AU (1) AU2006256891B2 (enExample)
BE (1) BE2021C505I2 (enExample)
CA (1) CA2611646C (enExample)
ES (1) ES2380950T3 (enExample)
FR (1) FR21C1004I2 (enExample)
NL (1) NL301089I2 (enExample)
PL (1) PL1901773T3 (enExample)
PT (1) PT1901773E (enExample)
WO (1) WO2006131347A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343895B1 (en) * 2000-12-21 2008-06-18 ID Biomedical Corporation Streptococcus pyogenes antigens and corresponding dna fragments
EP2144681A4 (en) 2007-05-04 2011-10-05 Kurt G I Nilsson MATERIAL FOR THE DEPOSITION OF A BIOMOLECULAR
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
WO2010089126A2 (en) 2009-02-09 2010-08-12 Roche Glycart Ag Immunoglobulin glycosylation pattern analysis
AU2010240486B2 (en) * 2009-04-22 2014-09-18 Ofir Menashe Microorganism comprising particles and uses of same
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3149395A1 (en) * 2019-08-01 2021-02-04 Memorial Sloan-Kettering Cancer Center Cells for improved immunotherapy and uses thereof
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
CN120078887A (zh) * 2020-09-21 2025-06-03 上海宝济药业股份有限公司 一种药物组合及其应用
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2023116817A1 (zh) * 2021-12-22 2023-06-29 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体的用途
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
AU2023383441A1 (en) 2022-11-18 2025-06-05 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
CN122438692A (zh) * 2023-08-01 2026-07-21 英斯梅德股份有限公司 新型IgG蛋白酶及其使用方法
WO2025047848A1 (ja) 2023-08-30 2025-03-06 アステラス製薬株式会社 ＩｄｅＺ改変体
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051914A2 (en) * 2001-12-18 2003-06-26 Hansa Medical Research Aktiebolag Ides, an igg-degrading enzyme of streptococcus pyogenes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284747A2 (en) * 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051914A2 (en) * 2001-12-18 2003-06-26 Hansa Medical Research Aktiebolag Ides, an igg-degrading enzyme of streptococcus pyogenes

Also Published As

Publication number Publication date
NL301089I2 (nl) 2021-02-04
CA2611646A1 (en) 2006-12-14
US20100303781A1 (en) 2010-12-02
PT1901773E (pt) 2012-06-06
FR21C1004I2 (fr) 2022-01-14
WO2006131347A2 (en) 2006-12-14
ATE548049T1 (de) 2012-03-15
BE2021C505I2 (enExample) 2021-05-31
CA2611646C (en) 2015-08-11
AU2006256891A1 (en) 2006-12-14
NL301089I1 (enExample) 2021-01-20
WO2006131347A3 (en) 2007-05-31
PL1901773T3 (pl) 2012-09-28
CN105770871A (zh) 2016-07-20
EP1901773B1 (en) 2012-03-07
JP2008542418A (ja) 2008-11-27
FR21C1004I1 (enExample) 2021-03-26
ES2380950T3 (es) 2012-05-21
JP5427409B2 (ja) 2014-02-26
EP1901773A2 (en) 2008-03-26
US8133483B2 (en) 2012-03-13

Similar Documents

Publication Publication Date Title
CA2611646C (en) Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
AU2007331736B2 (en) Use of the endoglycosidase EndoS for treating immunoglobulin G mediated diseases
EP3668972B1 (en) Engineered dnase enzymes and use in therapy
US5863782A (en) Synthetic mammalian sulphamidase and genetic sequences encoding same
JPS63503275A (ja) ファクター８：ｃの製造方法
CN101232900B (zh) IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
JPH11253179A (ja) 新規グルコサミニダ―ゼ
EP2001499A2 (en) Use of tsg-6 for treating bone diseases
JPH07149654A (ja) アンギオゲニンの抑制剤
JPH1189585A (ja) 新規Ｄｅｆ１
JPH11266880A (ja) 新規ｄｂｐＡ
JPH11337548A (ja) 新規ＤｂｐＢ
US6524814B1 (en) Enzyme and DNA sequence encoding krill-derived multifunctional protein
US20230233652A1 (en) 28 kda gst proteins from schistosoma for the treatment of vasculitis
JP2001523114A (ja) スタフィロコッカス・アウレウス由来の３−ヒドロキシアシル−ｃｏａデヒドロゲナーゼ
WO2008024457A2 (en) Rnase a peptides, fragments and uses thereof
JPH11137277A (ja) 新規ｇｒｅＡ
WO2025172720A1 (en) Fragment of complement factor h related protein 5 which restores complement regulation
JPH1175877A (ja) 新規化合物
JPH1198991A (ja) 新規化合物
JPH11235182A (ja) 新規化合物
JPH11253172A (ja) ＭｅｃＢ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: HANSA BIOPHARMA AB

Free format text: FORMER NAME(S): HANSA MEDICAL AB

MK14 Patent ceased section 143(a) (annual fees not paid) or expired